4-Ethyl-2-methyloxazole | 53833-20-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-Ethyl-2-methyloxazole
• 英文别名: 4-ethyl-2-methyl-1,3-oxazole
• CAS: 53833-20-8
• 化学式: C₆H₉NO
• 分子量: 111.14
• InChiKey: FLRAVPRRUDBVKJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  26
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• [EN] NEPRILYSIN INHIBITORS<br/>[FR] INHIBITEURS DE LA NÉPRILYSINE
  申请人：THERAVANCE BIOPHARMA R & D IP LLC

  公开号：WO2015116786A1

  公开（公告）日：2015-08-06

  In one aspect, the invention relates to compounds having the formula (I): where R1-R6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising these compounds; methods of using these compounds; and processes and intermediates for preparing these compounds.

  在一方面，本发明涉及具有公式（I）的化合物：其中R1-R6定义如说明书中所述，或其药用可接受的盐。这些化合物具有中性粒细胞弹性蛋白酶抑制活性。在另一方面，本发明涉及包含这些化合物的药物组合物；使用这些化合物的方法；以及制备这些化合物的过程和中间体。
• Anti-Viral Compounds
  申请人：DeGoey David A.

  公开号：US20100168138A1

  公开（公告）日：2010-07-01

  Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

  描述了一种有效抑制丙型肝炎病毒（“HCV”）复制的化合物。本发明还涉及制备这种化合物的方法、包含这种化合物的组合物，以及使用这种化合物治疗HCV感染的方法。
• Modulators of LXR
  申请人：——

  公开号：US20030181420A1

  公开（公告）日：2003-09-25

  Compounds, compositions and methods for modulating the activity of nuclear receptors are provided. In particular, heterocyclic compounds are provided for modulating the activity of nuclear receptors, including liver X receptor (LXR) and orphan nuclear receptors. In certain embodiments, the compounds are N-substituted pyridones.

  提供了用于调节核受体活性的化合物、组合物和方法。具体来说，提供了用于调节核受体活性的杂环化合物，包括肝X受体（LXR）和孤儿核受体。在某些实施方式中，这些化合物是N-取代吡啶酮。
• [EN] CYCLOPENTYL GLUTARAMIDES AND THEIR USE AS NEUTRAL ENDOPEPTIDASE INHIBITORS<br/>[FR] GLUTARAMIDES CYCLOPENTYLE ET UTILISATION DE CES COMPOSES COMME INHIBITEURS D'ENDOPEPTIDASE NEUTRE (NEP)
  申请人：PFIZER LTD

  公开号：WO2004056787A1

  公开（公告）日：2004-07-08

  The invention relates to NEP inhibitors for treating cardiovascular disorders wherein R1 is C1-C6alkyl, C1-C6alkoxyC1-C3alkyl or C1-C6alkoxyC1-C6alkoxyC,-C3alkyl; R2 is hydrogen or C1-C6alkyl; L is an aromatic heterocyclic ring, optionally substituted with C,­ C6alkyl or halo; R3 is C1-C6alkyl optionally substituted by halo, alkoxy, haloalkoxy, alkylthio, haloalkylthio or nitrile group, or R3 is phenyl or aromatic heterocyclyl each of which may be independently substituted by one or more alkyl, halo, haloalkyl, alkoxy, haloalkoxy, alkylthio, haloalkylthio or nitrile group; R4 and R5 are either both hydrogen, or one of R4 and R5 is hydrogen and the other is a biolabile ester-forming group that in the body of a patient is replaced by hydrogen; p is 0, 1 or 2; and q is 1 or 2.

  该发明涉及NEP抑制剂，用于治疗心血管疾病，其中R1为C1-C6烷基，C1-C6烷氧基C1-C3烷基或C1-C6烷氧基C1-C6烷氧基，R2为氢或C1-C6烷基，L为芳香杂环环，可选择性地取代为C，C6烷基或卤素，R3为C1-C6烷基，可选择性地取代为卤素，烷氧基，卤代烷氧基，烷基硫醚，卤代烷基硫醚或腈基，或R3为苯基或芳香杂环基，每个基团可独立地取代为一个或多个烷基，卤素，卤代烷基，烷氧基，卤代烷氧基，烷基硫醚，卤代烷基硫醚或腈基；R4和R5要么都是氢，要么R4和R5中的一个是氢，另一个是在患者体内被氢取代的生物易降解酯基团；p为0、1或2；q为1或2。
• [EN] SUBSTITUTED HETEROAROMATIC PYRAZOLO-PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS<br/>[FR] PYRAZOLO-PYRIDINES HÉTÉROAROMATIQUES SUBSTITUÉES ET LEUR UTILISATION EN TANT QUE MODULATEURS DU RÉCEPTEUR GLUN2B
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2020249785A1

  公开（公告）日：2020-12-17

  Substituted Pyrazolo-pyridines as GluN2B receptor ligands. Such compounds may be used in GluN2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by GluN2B receptor activity.

  替代性吡唑并吡啶作为GluN2B受体配体。此类化合物可用于GluN2B受体调节，以及用于治疗由GluN2B受体活性介导的疾病状态、紊乱和条件的药物组合物和方法。